Show summary Hide summary
A new analysis linking genetic data with patient-reported outcomes suggests some people respond slightly better to popular weight-loss injections — and that genetics may also explain who is most likely to feel sick while taking them. The findings, published in Nature and based on tens of thousands of users, point to modest but measurable differences that could matter as clinicians weigh treatment options for millions trying GLP-1–based therapies.
The study examined genetic information from more than 27,000 people who reported using modern weight-loss drugs, including medications such as semaglutide and tirzepatide. Researchers focused on variants in receptors targeted by these therapies and compared those genotypes to self-reported weight change and side-effect reports.
One particular change in the GLP1R gene was associated with a small boost in outcomes: carriers of a single copy lost, on average, about 1.6 pounds more than non-carriers. That difference sits against a much larger overall mean weight loss among participants — roughly 24 pounds — so the genetic effect is detectable but not dramatic.
US to restart nonstop commercial flights to Caracas after 7-year pause
MLB contenders on the brink: 3 teams must solve key problems before playoff push
Another genetic signal, involving the GIPR gene, correlated with higher frequencies of nausea and vomiting. Importantly, researchers found that experiencing these gastrointestinal side effects did not reduce the amount of weight participants ultimately lost; they simply reported more discomfort during treatment.
Key takeaways
- Modest genetic influence: A GLP1R variant corresponded to an average additional loss of ~1.6 pounds per carrier.
- Substantial average benefit: Participants overall reported about a 24-pound mean reduction in weight across the cohort.
- Side-effect link: Separate genetic differences were tied to increased reports of nausea and vomiting, without lowering drug effectiveness.
- Demographic patterns: Women in the study showed greater average BMI reduction (about 12.2%) than men (about 10.0%).
Study authors and collaborators framed the results as an early step toward more individualized prescribing. “These findings point to a future where genetic information helps inform which patients may tolerate a medication better or respond more strongly,” one investigator involved in the research said, noting the potential to refine treatment decisions.
Clinicians not involved in the work welcomed the idea but urged caution. A hormone and weight-management specialist noted surprise at the wide reported range in nausea risk and at some drug-specific genetic patterns that emerged. He described the results as hypothesis-generating rather than conclusive guidance for practice.
Limits of the research
The authors and outside experts flagged several important caveats. Most data were self-reported, which introduces potential bias: in a sub-study that compared participant claims with passively collected smartphone health data, self-reported weight loss averaged 11.8% while the phone-recorded subset showed about 5.8% — a substantial gap.
The participant pool came from a consumer genetics research cohort that is not fully representative of the broader population. The study also lacked information on key clinical endpoints such as diabetes progression and rare but serious adverse events like gastroparesis or pancreatitis. Finally, because the analysis is observational rather than a randomized trial, it can identify associations but cannot prove genetic variants cause differences in outcomes.
Given those limitations, the study’s practical takeaway is cautious: genetic testing could become a tool to help personalize weight-loss treatment, but it is not yet a definitive guide for choosing or avoiding specific medications.
Why this matters now
Use of GLP-1–based therapies has surged, bringing both rapid benefits and new questions about side effects and long-term safety. If follow-up research — ideally randomized and more diverse in sample composition — confirms these early signals, genetics might help clinicians predict who will gain the most benefit, who is likely to struggle with side effects, and when alternative approaches should be considered.
For patients and doctors, the immediate implication is to view genetic findings as an additional data point rather than a decision rule: useful context, not a replacement for clinical judgment and careful monitoring.
